Innate Pharma has been granted a patent for methods to treat cancer using anti-NKG2A antibodies. The patent details a specific antibody composition and a therapeutic regimen involving bi-monthly intravenous administration, aimed at neutralizing NKG2A’s inhibitory effects to enhance treatment efficacy. GlobalData’s report on Innate Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Innate Pharma, Personalized cancer vaccines was a key innovation area identified from patents. Innate Pharma's grant share as of June 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Cancer treatment using anti-nkg2a antibodies
The granted patent US12037392B2 outlines a method for treating cancer using an anti-NKG2A antibody that specifically binds to and neutralizes the inhibitory activity of the NKG2A receptor. The claims detail that the antibody consists of a heavy chain and a light chain with specific sequences (SEQ ID NO: 3 and SEQ ID NO: 7, respectively) and is designed to compete with HLA-E for binding to NKG2A. The treatment regimen involves administering the antibody intravenously to the patient at a dosage ranging from 4 to 10 mg/kg body weight, with a recommended frequency of twice per month. The method allows for flexibility in dosing, including an initial loading dose of 10 mg/kg followed by maintenance doses of 4 mg/kg.
The patent further specifies that the method can be applied to individuals with various types of cancer, including hematological tumors and solid tumors. Notably, it mentions specific cancers such as lung cancer and head and neck squamous cell carcinoma (HNSCC), with HNSCC encompassing oropharyngeal, larynx, oral cavity, and hypopharynx tumors. The treatment cycle is designed to include at least four administrations of the antibody, ensuring a structured approach to therapy. This patent presents a targeted therapeutic strategy aimed at enhancing the immune response against cancer by inhibiting the NKG2A pathway.
To know more about GlobalData’s detailed insights on Innate Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
